Lähteet

  1. Fredholm B.B. et al. (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev, 51:83-133.
  2. Illy A. et al. (1995) Espresso Coffee. The chemistry of quality. Academic Press, London.
  3. Harland B.F. (2000) Caffeine and nutrition. Nutrition, 7/8:522-526.
  4. Heckman M.A. et al. (2010) Caffeine (1, 3, 7-trimethylxanthine) in foods: a comprehensive review on consumption, functionality, safety, and regulatory matters. J Food Sci, 75:R77-87.
  5. Cornelis M. et al. (2007) Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption. Am J Clin Nutr, 86:240-244.
  6. Sachse C. et al. (1999) Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol, 47(4):445-9.
  7. Scientific Committee for Food (1983) Report of the Scientific Committee for Food on Caffeine.
  8. Health Canada. (2013) Health Canada Reminds Canadians to Manage Their Caffeine Consumption http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/34021a-eng.php
  9. CARE Study Group (2008) Maternal caffeine intake during pregnancy and risk of fetal growth restriction: a large prospective observational study. Br Med J, 337:a2332.
  10. March of Dimes (2012) Caffiene in Pregnancy http://www.marchofdimes.com/pregnancy/caffeine-in-pregnancy.aspx
  11. Ellison R.C. et al. (1995) Current caffeine intake of young children: amount and sources. J Am Diet Assoc, 95(7):802-4.
  12. Mitchell D.C. et al. 2013, Beverage caffeine intakes in the U.S. Food Chem Toxicol, 2013 Nov 1. [Epub ahead of print]
  13. Porkka-Heiskanen T. (2011) Methylxanthines and sleep. Handb Exp Pharmacol, 200:331-48.
  14. Rétey J.V. et al. (2007) A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin Pharmacol Ther, 81:692-8.
  15. Byrne E.M. et al. (2012) A genome-wide association study of caffeine-related sleep disturbance: confirmation of a role for a common variant in the adenosine receptor. Sleep, 35(7):967-75.
  16. Alsene K. et al. (2003) Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology, 28(9):1694-702.
  17. Rogers P.J. et al. (2010) Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption. Neuropsychopharmacology, 35(9):1973-83.
  18. Booth D.A. et al. (1992) Personal benefits from post-ingestional actions of dietary constituents. Proc Nutr Soc, 51:335–341.
  19. French J.A. et al. (1994) Caffeine and mood: individual differences in low-dose caffeine sensitivity. Appetite, 22: 277–279.
  20. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM V) ISBN 978-0-89042-554-1DSMV.
  21. Nehlig A. (1999) Are we dependent upon coffee and caffeine? A review on human and animal data. Neurosci Biobehav Rev, 23(4): 563-76.
  22. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2011) Scientific Opinion on the substantiation of health claims related to caffeine and increased fat oxidation leading to a reduction in body fat mass (ID 735, 1484), increased energy expenditure leading to a reduction in body weight (ID 1487), increased alertness (ID 736, 1101, 1187, 1485, 1491, 2063, 2103) and increased attention (ID 736, 1485, 1491, 2375) pursuant to Article 13(1) of Regulation (EC) No 1924/20061. EFSA Journal; 9(4):2054.
  23. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2011) Scientific Opinion on the substantiation of health claims related to caffeine and increase in physical performance during short-term high-intensity exercise (ID 737, 1486, 1489), increase in endurance performance (ID 737, 1486), increase in endurance capacity (ID 1488) and reduction in the rated perceived exertion/effort during exercise (ID 1488, 1490) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal; 9(4): 2053 [24 pp.]. doi:10.2903/j.efsa.2011.2053
  24. Santos C. et al. (2010) Caffeine intake and dementia: systematic review and meta-analysis. J Alzheimers Dis, 20 Suppl1: S187-204.
  25. Arendash G.W. et al. (2006) Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience, 142(4):941-52.
  26. Cao C. et al. (2009) Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer’s disease transgenic mice. J Alzheimers Dis, 17(3):681-97.
  27. Costa J. et al. (2010) Caffeine exposure and the risk of Parkinson’s disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis, 20 Suppl 1:S221-38.
  28. Chen J.F. (2003) The adenosine A(2A) receptor as an attractive target for Parkinson’s disease treatment. Drug News Perspect, 16(9):597-604.
  29. Pelchovitz D.J. et al. (2011) Caffeine and cardiac arrhythmias: a review of the evidence. Am J Med, 124(4): 284-9.
  30. Caldeira D. et al. (2013) Caffeine does not increase the risk of atrial fibrillation: a systematic review and meta-analysis of observational studies. Heart, 99(19):1383-9.
  31. Rauh R. et al. (2006) Acute effects of caffeine on heart rate variability in habitual caffeine consumers. Clin Physiol Funct Imaging, 26(3):163-6.
  32. Mostofsky E. et al. (2012) Habitual coffee consumption and risk of heart failure: a dose-response meta-analysis. Circ Heart Fail, 5(4):401-5.
  33. Wu J.N. et al. (2009) Coffee consumption and risk of coronary heart diseases: a meta-analysis of 21 prospective cohort studies. Int J Cardiol, 137(3):216-25.
  34. Noordzij M. et al. (2005) Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J Hypertens, 23(5):921-8.
  35. Palatini P. et al. (2009) CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens, 27(8):1594-601.
  36. Geleijnse J.M. (2008) Habitual coffee consumption and blood pressure: an epidemiological perspective. Vasc Health Risk Manag, 4(5):963-70.
  37. Du Y. et al. (2005) Association of serum caffeine concentrations with blood lipids in caffeine-drug users and nonusers – results of German National Health Surveys from 1984 to 1999. Eur J Epidemiol, 20(4):311-6.
  38. Jee S.H. et al. (2001) Coffee consumption and serum lipids: a meta-analysis of randomized controlled clinical trials. Am J Epidemiol, 153(4):353-62.
  39. Verhoef P. et al. (2002) Contribution of caffeine to the homocysteine-raising effect of coffee: a randomized controlled trial in humans. Am J Clin Nutr, 76(6):1244-8.
  40. Ruxton C.H.S. (2008) The impact of caffeine on mood, cognitive function, performance and hydration: a review of benefits and risks. Nutr Bull, 33:15–25.
  41. Armstrong L.E. et al. (2007) Caffeine, fluid-electrolyte balance, temperature regulation, and exercise-heat tolerance. Exerc Sport Sci Rev, 35(3):135-40.
  42. Heaney R.P. (2002) Effects of caffeine on bone and the calcium economy. Food Chem Toxicol, 40:1263-70.
  43. Liu H. et al. (2012) Coffee consumption and risk of fractures: a meta-analysis. Arch Med Sci, 8(5):776-83.
  44. Hallström H. et al. (2013) Long-term coffee consumption in relation to fracture risk and bone mineral density in women. Am J Epidemiol, 178(6):898-909.
  45. Boekema P.J. et al. (2001) Functional bowel symptoms in a general Dutch population and associations with common stimulants. Netherlands J Med, 59(1):23-30.
  46. Moayyedi P. et al. (2000) The Proportion of Upper Gastrointestinal Symptoms in the Community Associated with Helicobacter pylori: Lifestyle Factors, and Non-Steroidal Anti-inflammatory drugs. Am J Gastroenterol, 95 (6):1448-1455.
  47. Rubach M. et al. (2011) Multi-parametric approach to identify coffee components that regulate mechanisms of gastric acid secretion. Mol Nutr Food Res, 56(2):325-35.
  48. Kim J. et al. (2013) Association between coffee intake and gastroesophageal reflux disease: a meta-analysis. Dis Esophagus. 2013 Jun 24.doi: 10.1111/dote.12099. [Epub ahead of print].
  49. Shimamoto T. et al. (2013) No Association of Coffee Consumption with Gastric Ulcer, Duodenal Ulcer, Reflux Esophagitis, and Non-Erosive Reflux Disease: A Cross-sectional study of 8,013 Healthy Subjects in Japan. PLoS One, 8(6); e65996.
  50. EFSA (2011) ‘The EFSA Comprehensive European Food Consumption Database’ Available at: http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb.htm
  51. Mitchell D.C. et al. (2014) Beverage caffeine intakes in the U.S. Food & Chemical Toxicology, 63:136-142
  52. Branum A.M. et al. (2014) Trends in caffeine intake among U.S. children and adolescents, Pediatrics, 133(3):386-393
  53. Meltzer H M. et al. (2008) Risk assessment of caffeine among children and adolescents in the Nordic countries, Nordic Council of Ministers
  54. Rudolph E. et al. (2014) Caffeine intake from all sources in adolescents and young adults in Austria, European Journal of Clinical Nutrition, 68(7):793-8
  55. Ruxton C.H.S. (2014) The suitability of caffeinated drinks for children: a systematic review of randomised controlled trials, observational studies and expert panel guidelines, Journal of Human Nutrition & Dietetics, 27:342-357



Tiedot on suunnattu terveydenhuollon ammattilaisille ja ravitsemusasiantuntijoille.